Hormone replacement therapy and symptom reporting in menopausal women: a population-based study of 35-65-year-old women in mid-Sweden.

Maturitas

Family Medicine and Clinical Epidemiology Sections, Department of Public Health and Caring Sciences, Uppsala University, Uppsala Science Park, 751 85 Uppsala, Sweden.

Published: January 2002

Objective: To measure the prevalence rate of hormone replacement therapy (HRT) in the general population and to see whether HRT users report less symptoms, better general health and less use of other palliative than non-users and previous users.

Methods: The study was performed in 1995 as a cross-sectional postal questionnaire study in seven counties in mid-Sweden. The questionnaire was sent to a random sample of 4200 35-64-year-old women of whom 2991 responded. The age distribution of responders and non-responders was similar 49.6+/-8.5 and 49.8+/-8.7 years, respectively. The main outcome measures were vasomotor and general symptoms in relation to menstrual status and HRT.

Results: Fifteen percent were on HRT and 2.3% had stopped treatment during the past year. Thirteen percent used other palliatives. Twenty-five percent of premenopausal women experienced any vasomotor symptoms, as compared with 51% of menopausal and 40% of postmenopausal women. Those on HRT reported higher frequencies than non-users of all symptoms except for sweating during the daytime. In addition, menopausal women experienced more of other symptoms, usually not associated with the menopause, than premenopausal and postmenopausal women. HRT users reported a significantly worse perceived health and they took other palliatives drugs to a larger extent than HRT non-users.

Conclusion: HRT seemed to be effective in relieving some vasomotor symptoms but did not affect the prevalence of other symptoms or perceived health, in spite of the fact that women on HRT supplemented their therapy with palliative drugs to a larger extent than other women.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0378-5122(01)00254-7DOI Listing

Publication Analysis

Top Keywords

women hrt
12
women
9
hormone replacement
8
replacement therapy
8
menopausal women
8
hrt
8
hrt users
8
women experienced
8
vasomotor symptoms
8
postmenopausal women
8

Similar Publications

Hormone replacement therapy for steatotic liver management after surgical menopause.

Clin J Gastroenterol

January 2025

Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.

Although steatotic liver onset after natural menopause has been reported, evidence on the clinical course and treatment options for steatotic liver after surgical menopause is scarce. A 34-year-old woman with a history of severe obesity presented to our department with liver dysfunction following total hysterectomy and bilateral oophorectomy. Her serum estradiol level was notably low at 22 pg/mL, and a liver biopsy revealed significant fatty degeneration, lobular inflammation, hepatocyte ballooning, and stage F1 fibrosis.

View Article and Find Full Text PDF

Purpose: To compare the efficacy of modified natural cycle (mNC) preparation versus hormone replacement therapy (HRT) for endometrial preparation in recipients of donated oocytes, specifically focusing on pregnancy rates in women of advanced maternal age.

Methods: Retrospective multicenter analysis conducted between 2021 and 2024. It includes 220 cycles of fresh single blastocyst transfers resulting from oocyte donation.

View Article and Find Full Text PDF

BARRIERS TO PRESCRIPTION OF HORMONAL CONTRACEPTION AND HORMONE REPLACEMENT THERAPY IN GYNECOLOGICAL CANCER SURVIVORS: RESULTS OF A SURVEY AND LITERATURE REVIEW.

J Gynecol Obstet Hum Reprod

December 2024

Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal; Portuguese Gynecologic Oncology Section of the Portuguese Society of Gynecology. Electronic address:

Background: The incidence of gynecological cancers in premenopausal women is increasing, highlighting issues related to Hormonal Contraception (HC) and Hormone Replacement Therapy (HRT). However, the presence of hormonal receptors in many gynecological cancers complicates HC and HRT prescriptions.

Objective: To identify barriers experienced by gynecologists in prescribing HC and HRT to gynecological cancer survivors, with a secondary objective of conducting a literature review on the safety of these prescriptions.

View Article and Find Full Text PDF

Background: In postmenopausal women who are estrogen deficient, hormone replacement therapy (HRT) has been shown to improve fragility fracture risk. However, few studies have examined the relationship between HRT and periprosthetic fracture (PPF) risk after total hip arthroplasty (THA). The purpose of this study was to determine the impact of HRT use on 10-year PPF risk following THA.

View Article and Find Full Text PDF

Background: In freeze-thawed embryo transfer (FET) cycles, hormone replacement treatment (HRT) is crucial for implantation and pregnancy maintenance. HRT typically continues until the 10th week of pregnancy owing to a luteoplacental shift, although a definitive HRT regimen remains undetermined. We present the case of a woman who underwent FET during an HRT cycle and ceased HRT after a negative pregnancy test at 3 weeks and 5 days, who went on to deliver a healthy baby.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!